Skip to main content
Envío gratis en todos los pedidos
888-559-3802
VitabaseIngredientes

coco

Condiciones de Salud22
Tabla de contenidos

Otros Nombres

Bahia coconut palmCalappa nucifera (L.) Kuntzecoccococococo blancococo da Indiacoco de aguacoco de Bahiacoco indiococo moradococo-da-bahiacoco-da-índiacoconut palmcoconut treecoconut-of-the-beachcocosCocos indica RoyleCocos nana GriffithCocos nucifera L.Cocos nucifera var. laetevirens BlumeCocos nucifera var. lansiformis BlumeCocos nucifera var. lolog BlumeCocos nucifera var. machaeroides BlumeCocos nucifera var. macrocarpa BlumeCocos nucifera var. maldivica BlumeCocos nucifera var. mamillaris (Blanco) BlumeCocos nucifera var. nana (Griff.) G.V.NarayanaCocos nucifera var. ossea BlumeCocos nucifera var. palmyrensis (Becc.) Becc.Cocos nucifera var. synphyllica Becc.cocospalmcocoterococotiercocoyercopracoqueirocoqueiro-da-bahiacoqueiro-da-índiadaabdabdôongdừainaiá-guaçuíbainajá-guaçújawz hindījooz al-hindkalapakelapaklapperboomkobbarakobbarikobbarichettuKokkofoinikaKokosKokosnootKokosnussKokosnusspalmeKokospalmKokospalmekookospähkinäkookospalmkookospalmuma phraonaliyernarakelnaralnarcolenarelnargilnargilehnarikelnarikelanārikelanarikelamnarikelamunariyalnariyelanarla maddenarlunaryalniogniuniyognizoknoix de coconux indicanyiurPalma cocos Mill.palma de cocopalmera cocoterapalmera de cocophaawzpolshriphaltengaitenginatengina-kayitengutenkaayatenkaitenkayatenkutennatennaitennaimaramthengathengaithengina kayithenguthennaye zi

Sinopsis

La metenamina, también conocida como hexametilentetramina o urotropina, es un compuesto sintético utilizado principalmente como antiséptico urinario. Es un polvo cristalino blanco que es inactivo en su forma original pero se vuelve antibacteriano en entornos ácidos al hidrolizarse en formaldehído, que tiene actividad antimicrobiana de amplio espectro.

La metenamina se usa más comúnmente para la prevención de infecciones urinarias recurrentes (UTIs), especialmente en pacientes con infecciones crónicas o complicadas que pueden no responder bien a los antibióticos convencionales. Debido a que su efecto antibacteriano depende de la acidez de la orina (pH < 6), a menudo se prescribe junto con acidificantes urinarios como el ácido ascórbico (vitamina C) o el fosfato ácido de sodio para garantizar una activación adecuada.

A diferencia de los antibióticos tradicionales, la metenamina no promueve la resistencia bacteriana porque su mecanismo —liberar formaldehído— es inespecífico y bactericida. Es activa contra una amplia gama de patógenos urinarios, incluyendo E. coli, Enterococcus y especies de Proteus, pero no es efectiva en presencia de orina alcalina o en infecciones activas que requieren terapia inmediata y dirigida.

La metenamina está disponible típicamente en dos formas de sal:

  • Hipurato de metenamina: A menudo utilizado para la prevención a largo plazo de UTIs en mujeres.
  • Mandelato de metenamina: Ligeramente más ácido y a veces preferido para pacientes con un pH urinario más elevado.

No es adecuada para su uso en pacientes con insuficiencia renal, deshidratación grave o deterioro hepático, y generalmente se reserva para uso profiláctico en lugar del tratamiento de infecciones agudas. Los efectos secundarios comunes pueden incluir náuseas, malestar estomacal o irritación de la vejiga, pero generalmente es bien tolerada en el uso a largo plazo.

Uso Histórico
La metenamina fue sintetizada por primera vez en 1860 por Aleksandr Butlerov, un químico ruso, pero su uso medicinal no fue reconocido hasta principios del siglo XX. Inicialmente, fue investigada como desinfectante químico antes de que se descubrieran sus propiedades antisépticas urinarias. Para las décadas de 1930 y 1940, la metenamina se convirtió en un tratamiento establecido para las afecciones urinarias crónicas, especialmente antes de la disponibilidad generalizada de las sulfonamidas y los antibióticos modernos.

Su capacidad para prevenir la colonización bacteriana sin fomentar la resistencia la mantuvo relevante incluso después de que los antibióticos se volvieron comunes. Durante muchas décadas, la metenamina fue una de las pocas opciones de profilaxis a largo plazo para UTIs disponibles, particularmente útil en pacientes de edad avanzada, aquellos con catéteres permanentes o pacientes con anomalías anatómicas del tracto urinario.

En años más recientes, la metenamina ha experimentado un renovado interés debido a la creciente preocupación por la resistencia a los antibióticos. Las guías clínicas ahora apoyan su uso en casos seleccionados para la prevención no antibiótica de UTIs, convirtiéndola en una herramienta importante en las estrategias de administración antimicrobiana.

Aunque no deriva de la medicina herbal o tradicional, la metenamina ocupa un espacio único en la atención integrativa moderna, particularmente para pacientes que buscan apoyo no antibiótico para la salud urinaria bajo supervisión médica.

Condiciones de Salud

Condiciones de salud que coco puede ayudar a apoyar.

  • HipocondríaCientífico

    VCO contains polyphenols, tocopherols, and phytosterols with measurable antioxidant activity in vitro and in preclinical models. In vitro studies confirm VCO reduces oxidative markers; animal studies show reduced malondialdehyde and increased antioxidant enzyme activity. Clinical human trial evidence for systemic antioxidant effects is limited.

  • Coconut oil's medium-chain fatty acids—lauric, capric, and caprylic acid—demonstrate antifungal activity in vitro against dermatophytes including Trichophyton spp., the primary causative organisms of tinea pedis. In vitro studies show zone-of-inhibition activity against relevant fungal isolates. Clinical human RCT evidence directly for athlete's foot is absent; the evidence base is in vitro and preclinical. Coconut oil is used as a carrier for more potent antifungal agents such as tea tree oil.

  • Multiple meta-analyses of RCTs find that coconut oil's acute effect raises postprandial glucose while decreasing insulin response. Long-term glycemic markers are not significantly altered compared to other cooking oils in most analyses, though one systematic review suggests coconut oil may increase insulin resistance. Evidence is mixed and overall quality is low to moderate.

  • VCO has been evaluated in preclinical burn wound models and nanoemulsion formulations. Animal studies demonstrate pro-healing effects attributed to anti-inflammatory, antioxidant, and antimicrobial properties. No high-quality human clinical trials specifically for burns have been published; current human-wound evidence is rated Level 5 (expert opinion / animal data only).

  • In vitro studies demonstrate that VCO's MCFAs (lauric acid, caprylic acid) inhibit Candida albicans at measurable MIC values, with activity comparable to ketoconazole in one study. A murine dietary study showed coconut oil reduced GI C. albicans colonization versus beef tallow. Clinical human data remain limited to indirect measures and in vitro models.

  • In vitro data confirm VCO MCFAs inhibit C. albicans colonization. A mouse dietary study (PubMed, 2016) showed a coconut oil-rich diet reduced GI C. albicans colonization versus beef tallow and soybean oil diets, supporting a potential dietary candida-reduction effect. Human RCT data for a 'candida cleanse' protocol are absent.

  • Multiple meta-analyses of clinical trials consistently demonstrate coconut oil raises both LDL-C and HDL-C versus unsaturated vegetable oils. A 16-trial meta-analysis (Neelakantan et al., Circulation 2020) found +10 mg/dL LDL-C and +4 mg/dL HDL-C. A 14-RCT VCO meta-analysis found VCO raised HDL-C and had variable LDL-C effects depending on the comparator fat.

  • ApendicitisCientífico

    In vitro studies show VCO suppresses key pro-inflammatory cytokines including TNF-α, IL-6, IL-5, and IL-8 in human monocytes and keratinocytes. RCT data on inflammatory biomarkers such as CRP are inconsistent, with most meta-analyses showing no significant reduction in CRP vs. comparator oils.

  • IncontinenciaCientífico

    Coconut oil provides MCTs metabolized to ketones, an alternative brain fuel when glucose metabolism declines with age and in Alzheimer's disease. A systematic review and meta-analysis found MCTs in coconut oil may improve cognitive abilities and potentially slow AD progression. Short-term cognitive benefits are documented in some RCTs, but evidence is classified as low quality overall.

  • Level 1 RCT evidence supports topical VCO for mild-to-moderate atopic dermatitis in children and adults. WHAM assigned Level 1 evidence for dermatitis. A SCORAD-assessed RCT in pediatric AD found VCO superior to mineral oil at 8 weeks. VCO reduces TEWL, improves skin hydration, and reduces S. aureus colonization.

  • AutismoCientífico

    A published RCT conducted in a neonatal ICU specifically evaluated coconut oil versus standard of care for prevention of diaper dermatitis (ScienceDirect, 2023). Coconut oil's antimicrobial and emollient properties are mechanistically plausible for diaper rash prevention and treatment; direct human trial evidence exists at the neonatal level.

  • EructosCientífico

    Level 1 RCT evidence demonstrates topical VCO is effective for xerosis (clinically dry skin), performing comparably to or better than mineral oil. A WHAM evidence summary assigned Grade B recommendation for VCO in mild-to-moderate xerosis. Application twice daily to affected areas is the established dosing protocol.

  • Multiple RCTs support topical VCO for atopic dermatitis (eczema). A double-blind RCT in 52 adults found VCO reduced SCORAD severity and cleared S. aureus colonization more effectively than virgin olive oil. A pediatric RCT confirmed VCO superior to mineral oil on SCORAD, TEWL, and skin capacitance after eight weeks.

  • Antojos de grasaCientífico

    MCTs from coconut oil contribute to ketone production. The classical MCT-based ketogenic diet is an established, evidence-based treatment for drug-resistant childhood epilepsy. Whole coconut oil has lower MCT density than refined MCT oil used clinically, but it is a dietary source supporting ketogenesis relevant to epilepsy management.

  • FatigaCientífico

    VCO has documented in vitro antifungal activity against dermatophytes (Trichophyton, Aspergillus, Rhizopus) and Candida. A 2023 RCT evaluated VCO as adjuvant to systemic antifungals in chronic dermatophytoses. MCFA content—lauric, capric, caprylic acids—disrupts fungal cell membranes.

  • Multiple RCTs confirm that coconut oil pulling reduces plaque index, gingival index, and periodontal pathogenic bacteria. A 2025 triple-blind RCT found VCO pulling comparable to chlorhexidine in reducing bacterial load and inflammatory markers in chronic periodontitis patients, with favorable effects on oral microbiome composition.

  • RCT meta-analyses find coconut oil does not significantly reduce body weight, BMI, waist circumference, or body fat percentage compared to other fats. MCTs within coconut oil may modestly increase satiety and thermogenesis in short-term studies, but purified MCT oil rather than whole coconut oil drives these effects.

  • JuanetesCientífico

    Clinical trial data and meta-analyses consistently show coconut oil raises both LDL-C and HDL-C relative to unsaturated vegetable oils. Mainstream cardiovascular bodies including the American Heart Association do not support coconut oil as heart-healthy due to LDL-raising effects. Epidemiological data from traditional coconut-consuming populations are confounded by overall diet patterns.

  • EscalofríosCientífico

    Small clinical trials and systematic reviews show coconut/MCT oil reliably elevates plasma ketones, which can serve as an alternative brain fuel when glucose metabolism is impaired. Domain-specific memory improvements have been reported in mild cognitive impairment patients in some but not all trials. Evidence quality remains low.

  • MCTs in coconut oil are metabolized via the portal vein directly to the liver, bypassing lymphatic absorption, and are preferentially oxidized for energy rather than stored as fat. Animal studies show coconut oil diet suppressed weight gain and improved glucose tolerance versus lard. Human RCT data show no significant metabolic advantages over other cooking oils at typical doses.

  • A 2025 triple-blind RCT used 16S rRNA sequencing to show coconut oil pulling significantly shifted the oral microbiome in periodontitis patients, reducing pathogenic bacteria (Spirochaetaceae, Tannerellaceae) and increasing beneficial Streptococcaceae, with effects comparable to chlorhexidine.

  • DifteriaCientífico

    A systematic review of in vivo studies (PubMed/Scopus search) found four animal studies—covering excisional, burn, and diabetic wounds—all showing VCO promotes wound healing. Human evidence is limited; the WHAM evidence summary found no clinical trials of topical coconut on human wound healing.

Sistemas Corporales

Sistemas corporales que coco puede ayudar a apoyar.

  • No hay sistemas corporales disponibles.
Únete a nuestro boletín

Mantente informado. Mantente saludable.

Recibe consejos de suplementos de expertos, descuentos exclusivos y recomendaciones de productos en tu bandeja de entrada

coco | Vitabase